We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
-8.04%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$255M
AUM Growth
-$24.4M
Cap. Flow
+$13.3M
Cap. Flow %
5.21%
Top 10 Hldgs %
71.55%
Holding
30
New
5
Increased
10
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$13.3M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$8.33M
3
CTNM
Contineum Therapeutics
CTNM
+$7.85M
4
MRUS
Merus
MRUS
+$4.97M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$4.18M

Top Sells

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$15.8M
2
NMRA icon
Neumora Therapeutics
NMRA
+$5.72M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$2.82M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.63M
5
COGT icon
Cogent Biosciences
COGT
+$2.14M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITOS
26
DELISTED
iTeos Therapeutics
ITOS
– –
-195,704
Closed -$2M
NMRA icon
27
Neumora Therapeutics
NMRA
$302M
– –
-432,996
Closed -$5.72M
PHAT icon
28
Phathom Pharmaceuticals
PHAT
$692M
– –
-874,590
Closed -$15.8M
AVBP icon
29
ArriVent BioPharma
AVBP
$1.44B
– –
-47,266
Closed -$1.11M
LBPH
30
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
– –
-31,529
Closed -$1.05M
1
2

Similar funds

TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.32% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return
BCM
Bienville Capital Management New York $550M AUM 3.49% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $549M AUM 24.44% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Saturn V Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Saturn V Capital Management held 30 positions worth $255M, down 8.7% from $280M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Saturn V Capital Management deployed $13.3M of net new capital in Q4 2024, opening 5 new positions and adding to 10 existing holdings. Its largest new stake was Xenon Pharmaceuticals: 322,470 shares worth $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Crinetics Pharmaceuticals, an estimated $2.82M trimmed.

  • Saturn V Capital Management's largest Q4 2024 buy was Xenon Pharmaceuticals: 322,470 shares worth $12.6M.
  • Saturn V Capital Management added most to Syndax Pharmaceuticals in Q4 2024, an estimated $8.33M increase.
  • Saturn V Capital Management's biggest Q4 2024 reduction was Crinetics Pharmaceuticals, cutting an estimated $2.82M.
  • Saturn V Capital Management fully exited Phathom Pharmaceuticals in Q4 2024, selling an estimated $15.8M.
  • Saturn V Capital Management's ten largest holdings make up 72% of its $255M portfolio in Q4 2024.
  • Saturn V Capital Management opened 5 new positions and closed 6 in Q4 2024.
  • Saturn V Capital Management's portfolio value fell 8.7% quarter-over-quarter to $255M.

Based on Saturn V Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.